Difference between revisions of "Mitomycin (Mutamycin)"
Jump to navigation
Jump to search
| Line 28: | Line 28: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1981-08-24: Initial FDA approval |
*Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated [[Gastric cancer|adenocarcinoma of the stomach]] or [[Pancreatic cancer|pancreas]] in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. ''(No supporting studies are cited)'' | *Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated [[Gastric cancer|adenocarcinoma of the stomach]] or [[Pancreatic cancer|pancreas]] in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. ''(No supporting studies are cited)'' | ||
Revision as of 22:25, 4 May 2023
General information
Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Anal cancer
- Bladder cancer
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Esophageal cancer
- Gallbladder cancer
- Gastric cancer
- Head and neck cancer
- Malignant pleural mesothelioma
Diseases for which is was used
Patient drug information
- Mitomycin (Mutamycin) patient drug information (Chemocare)[3]
- Mitomycin (Mutamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1981-08-24: Initial FDA approval
- Uncertain date: Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. (No supporting studies are cited)
Also known as
- Generic names: mitomycin-C, MTC
- Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin
References
Categories:
- Drugs
- Intravenous medications
- Intravesical medications
- Vesicant
- Antitumor antibiotics
- Human DNA synthesis inhibitors
- Anal cancer medications
- Bladder cancer medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Gallbladder cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Malignant pleural mesothelioma medications
- Non-small cell lung cancer medications (historic)
- Pancreatic cancer medications (historic)
- FDA approved in 1981